Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904263 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.6b00044 | DOI Listing |
Publication Analysis
Top Keywords
series potent
8
potent selective
8
inhibitors cdk8
8
design development
4
development series
4
selective type
4
type inhibitors
4
cdk8 sorafenib
4
sorafenib starting
4
starting point
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!